Francesca Barone, CSO of Candel Therapeutics CADL, was recently interviewed by Biedex Markets.
Candel is a clinical-stage biopharmaceutical company focused on developing immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The company has two main platforms that are currently undergoing clinical trials.
Ms. Barone spoke about the company’s work in deadly brain cancers. Its candidate, CAN-3110, is currently undergoing phase 1 trials. It recently published exciting data from the trial showing promising results.
Watch the full interview here:
Featured photo by National Cancer Institute on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Biedex Markets.com. Biedex Markets does not provide investment advice. All rights reserved.
